Breaking News, Financial News

Financial Report: Hospira

Restructuring charges impact results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira   2Q Revenues: $1.0 billion (-3%) 2Q Loss: $2.5 million (earnings were $143.6 million 2Q11) YTD Revenues: $2.0 billion (-3%) YTD Earnings: $37.8 million (earnings were $293.5 million YTD11) Comments: Specialty Injectable Pharmaceuticals revenue was $644.2 million (-5%). Medication Management revenue was $255.1 million (+4%). Other Pharma revenues, which includes contract manufacturing services, were down 6% to $134.0 million. Restructuring costs were $32.2 million in the quarter comp...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters